ASX ANNOUNCEMENT

Actinogen updated investor presentation

Sydney 21 March 2019: Actinogen Medical (ASX: ACW, 'the Company') is pleased to release an updated Investor Presentation. The presentation will be used to update shareholders, investors and brokers as part of a non-deal roadshow across Australia. The presentation outlines Actinogen's key investment highlights, clinical progress and outlook.

The investor presentation includes further insights into the clinical efficacy endpoints used in the Phase II XanADu clinical trial (refer to slides 16-20). The seven efficacy endpoints are used in the trial to identify the cognitive domains most sensitive to Xanamem's potential efficacy. The endpoints are validated cognitive outcome assessments used in Alzheimer's disease research globally and are recognised and accepted by global regulators. Multiple endpoints de-risk development and there is no reliance on achieving any one individual endpoint to progress clinical development. The totality of the XanADu and additional studies' results, expected by mid-year 2019 (refer to slide 6), will inform the optimal clinical development pathway for Xanamem going forward.

Key Investment Highlights

- **Novel compound:** Actinogen's lead compound Xanamem has a novel mechanism of action targeting excess cortisol production in the brain. This cortisol hypothesis and its potential role in Alzheimer's disease has been validated by multiple independent research.
- **Targeted strategic market focus:** Alzheimer's disease addressable market worth >US$7.5bn with unmet needs and potential upside.
- **Advanced clinical stage asset:** Fully funded advanced clinical stage program with reported positive safety interim analysis of the XanADu Phase II Alzheimer's study, which has completed patient enrolment and is on track for results read-out in 2Q CY2019.
- **Potential value upside:** Well positioned to unlock further value in Alzheimer's disease and other indications, supported by significant big pharma interest.
- **De-risked opportunity:** Initiated nine additional Xanamem-related studies – all studies fully funded and value-adding to Xanamem data-base. Further pipeline development opportunities under evaluation.
- **Experienced leadership and advisors:** Significant drug development and biotech investment experience guided by key opinion leading clinicians and drug discovery teams.

ENDS

Actinogen Medical
Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
@BillKetelbey

Investor and Media Enquiries
Arthur Chan
WE Buchan
M: +61 2 9237 2805
E: arthurc@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US$250bn and is set to increase to US$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanaHES

XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalation study to assess the safety and tolerability of Xanamem™ 20mg & 30mg once daily in healthy elderly volunteers. Changes in cognitive performance from baseline to end-of-treatment will be measured as an exploratory efficacy outcome.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.

Investor Presentation

A novel approach to treating cognitive impairment and Alzheimer's disease

Dr. Bill Ketelbey: CEO & MD

March 2019

Actinogen Medical

Contents

Executive summary

Key investment highlights

What is Xanamem

Development pipeline

Key investment highlights

Actinogen is developing innovative treatments for cognitive impairment associated with neurodegenerative and metabolic diseases with an initial focus on Alzheimer‘s disease

Xanamem - lead compound

Targeted strategic market focus

Clinical stage asset

Potential value upside

De-risked opportunity

Experienced leadership

Xanamem

Actinogen's lead compound, Xanamem, is a novel drug designed to inhibit the production of cortisol in the brain with the potential to treat cognitive impairment and Alzheimer's disease

Well researched
In clinical stage development, with over 15 years of R&D completed, and A$40m invested to date

Well tolerated
Dosed >150 patients with acceptable clinical safety, toxicity and PK / PD[1] profile

Differentiated mechanism of action
Highly selective inhibitor of the 11βHSD1 enzyme in the brain which reduces excess cortisol production

Validated
Symptomatic and disease modifying effects (in vivo) and effective demonstration of cortisol hypothesis (in humans)

Well protected
Composition of matter IP coverage ≥ 2031, patents granted in all major markets

Xanamem is a novel, first-in-class, potent, orally bioavailable and brain-penetrant 11βHSD1 inhibitor

1. PK / PD: pharmacokinetic / pharmacodynamic

Clinical development and milestones

Well progressed Phase II clinical trial (XanADu) underpinned by additional value-adding studies and an exciting Xanamem pipeline for other potential indications



Xanamem

The cortisol hypothesis

Validation of the cortisol hypothesis

Mechanism of action

Xanamem research and development

Xanamem has been developed in response to evidence that there is a strong association between chronically raised cortisol levels in the blood and in the brain, and the development and progression of Alzheimer's disease

Xanamem is underpinned by over 15 years of R&D with A$40m invested in development

The cortisol hypothesis

A growing body of literature showing an association between cortisol and cognitive impairment

Medical publications: “Cortisol and Cognition”[1]



Medical publications: “Cortisol and Alzheimer’s”[1]



Actinogen is well positioned to leverage the growing significance of the relationship between cortisol and cognition

1. PubMed keyword search

Human pilot studies validate the cortisol hypothesis

Two pilot studies indicated inhibiting cortisol production in the brain improves cognitive function in healthy elderly men and subjects with Type 2 diabetes (11β-HSD1 inhibition with carbenoxolone – no longer commercially available)[1,2]

Verbal fluency: Study 1[1]



Verbal memory: Study 2[2]



Significant improvement in verbal fluency and verbal memory after only 4 and 6 weeks of treatment[1,2]

Source: 11β-Hydroxysteroid dehydrogenase inhibition improves cognition function in healthy elderly men and type 2 diabetics Sandeep et al., 2004 PNAS (vol. 101, no. 17) 6734-6739

1. Study 1: 10 healthy subjects Age 55-75 (Mean Age = 65.5 ± 5.5) receiving 100mg carbenoxolone 3 times daily compared to placebo for 4 weeks, in a double-blind randomised crossover study
2. Study 2: 12 type 2 diabetics (m=9; f=3) Age 52-70 (Mean Age = 60 ± 4.9) receiving 100mg carbenoxolone 3 times daily compared to placebo for 6 weeks, in a double-blind randomised crossover study.

Mechanism of action

Xanamem inhibits the activity of the 11βHSD1 enzyme, reducing the production of cortisol in the brain

Overview



Xanamem has potential in other diseases with possible cortisol induced cognitive impairment

- **Alzheimer's disease (key focus)**
- Diabetes
- Depression
- Schizophrenia
- Parkinson’s disease
- Down syndrome
- And more…

Xanamem research and development

Xanamem is underpinned by significant R&D investment and clinical progress over the last 15 years



1. Estimated timing of key milestones

XanADu

Efficacy considerations

XanADu Phase II clinical trial and milestones

Interim analysis

Favourable market dynamics

Competitive landscape

Big Pharma interest

XanADu is a global Phase II double-blind, randomised, placebo-controlled study asessing the efficacy and safety of Xanamem in patients with mild Alzheimer's disease

Enrolment complete with results expected in 2Q CY2019

Alzheimer‘s strategic focus underpinned by medical research

A growing body of medical literature supports the association between cortisol and Alzheimer‘s disease

Raised cortisol associated with Alzheimer’s disease[1]



Supported by growing body of medical literature


Archival Report

Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study

aibl

Many studies support the association between **cortisol and Alzheimer’s disease development and progression**[2]

A recent AIBL[3] study provided compelling evidence that elderly subjects with **higher plasma cortisol levels are at much greater risk of developing Alzheimer‘s disease**

This study[3] also demonstrated **that 50% of those aged 65+ have raised cortisol levels**

Research suggests that lowering cortisol levels may prevent the development / progression of Alzheimer’s disease

1. MCI: mild cognitive impairment; AD: Alzheimer’s Disease
2. Recent studies also support the association between cortisol and cognitive impairment associated with neuroendocrine dysfunction
3. Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer’s Disease: a 6-Year Prospective Cohort Study. Pietrzak et al., 2017. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2:45-52

Efficacy underpinned by animal model

Significant and rapid symptomatic and disease modifying effects demonstrated with significant improvement in cognition within one month, continuing out to 41 weeks

Cognition: 28 days treatment



Amyloid clearance: 28 days treatment



Results from the animal model studies underpin the significant potential of the Xanamem in Alzheimer's

Source: UE2316 in Tg2576 rodent model of Alzheimer's disease. Sooy, et al., 2015. Endocrinology 156 (12) 4592-4603
SEM: Standard Error of the Mean

XanADu Phase II clinical trial

Double-blind, randomised, placebo-controlled study to assess the efficacy and safety of Xanamem in subjects with mild Alzheimer's disease[1]

Xanamem treatment course
12 weeks

186 patients with mild Alzheimer's disease (enrolment complete)[2]

10mg daily
Xanamem for 12 weeks (vs. placebo)

Trial conducted at 25 sites in
AUS, USA and UK

Fully funded study, fully enrolled with results due in 2Q CY2019

1. Study registered on Clinicaltrials.gov: NCT02727699
2. Fully enrolled 26 November 2018

XanADu endpoints

XanADu's primary and secondary efficacy endpoints are validated cognitive outcome measures used in Alzheimer's disease research globally and accepted by all major regulatory bodies globally (including the FDA)

XanADu: primary and secondary efficacy endpoints[1]



Efficacy endpoints are **standard assessments used in Alzheimer's disease studies globally**

While overlapping in many areas, each endpoint measures **discrete domains and function of cognition**

XanADu is designed to **identify the cognitive domains most sensitive** to Xanamem's potential efficacy

Multiple endpoints de-risks development as it enables deep insight into the potential treatment outcomes with Xanamem

There is **no reliance on achieving any one individual efficacy endpoint** to progress Xanamem clinical development

A positive signal from any of the **major efficacy endpoints[2]** could be **considered a positive result**

XanADu's results will inform future clinical development

1. ADAS-COG14: Alzheimer's Disease Assessment Scales – Cognitive Subscale Score (version 14); ADCOMs: AD COMposite Scores (composite data derived from ADAS-COG14, CDR-SOB and MMSE); CDR-SOB: Clinical Dementia Rating Scale – Sum of Boxes; RAVLT: Rey Auditory Verbal Learning Test; MMSE: Mini-Mental Status Examination; NTB: Neuropsychological Test Batteries; NPI: Neuropsychiatric Inventory
2. Major efficacy endpoints include: ADAS-COG14, ADCOMS,CDR-SOB, MMSE

Key takeaways for XanADu efficacy endpoints[1]

- Results will inform on **efficacy, safety and potential utility** of Xanamem in Alzheimer's disease patients
- Each clinical efficacy endpoint has **many domains resulting in numerous potential outcomes**
- **No individual endpoint must be achieved** to progress Xanamem development
- Actinogen and its **expert Clinical Advisory Board will assess all** endpoint results
- Results **will inform design of future trials** in development of Xanamem
- The **totality of the endpoint results**[2] will assist in informing the optimal way forward for Xanamem development

1. Actinogen believes there are no safety concerns with 10mg Xanamem daily in mild Alzheimer's patients – following 2 successful DSMB interim reviews and ongoing surveillance of all safety data
2. Results from XanADu and the additional studies initiated since mid-2018

XanADu primary efficacy endpoints

A primary endpoint is the endpoint to which a clinical trial is powered for statistical purposes[1]; XanADu is powered to ADAS-COG14 (ADCOMS is a co-primary endpoint)

ADAS-COG14
AD Assessment Scale Cognition (version 14)

- One of the **most frequently used tests** to measure cognition status and commonly used in Alzheimer's disease drug development
- Considered a **"gold standard" endpoint** in Alzheimer's disease research globally
- **Widely accepted** by global regulators, academics and potential strategic partners
- XanADu is **statically designed around this endpoint**

Language

Memory

ADCOMS
AD Composite Score

- **Composite of most sensitive domains** of ADAS-COG, CDR-SOB and MMSE
- A **statistically positive result would likely indicate a positive trend** in many or all of the above domains[2]
- Breakthrough instrument that is **expected to be a routine test** to investigate treatment of mild Alzheimer's disease
- **Adequately powered for XanADu** given sensitivity

Language

Orientation, time

Memory, judgement and problem solving

Community affairs, home & hobbies, and personal care

1. Defines how many patients are needed to achieve statistical significance
2. If a statistically positive result is not achieved in ADAS-COG, CDR-SOB, or MMSE, or only a trend towards a positive outcome is achieved, it is still possible that there could be a statistically significant outcome with ADCOMS – as ADCOMS selects for the most sensitive outcome domains in mild cases of Alzheimer's disease

XanADu secondary efficacy endpoints

XanADu's secondary efficacy endpoints complement the primary endpoints and provide additional information about the therapeutic efficacy of the drug candidate to inform further clinical development

CDR-SOB[1]	MMSE	RAVLT	NTB	NPI
Clinical Dementia Rating Sum of Boxes	*Mini-Mental State Examination*	*Rey Auditory Verbal Learning Test*	*Neuropsychological Test Battery*	*Neuropsychiatric Inventory*

Key domains assessed

CDR-SOB	MMSE	RAVLT	NTB	NPI
Memory, judgement and problem solving	Recent memory	Verbal learning	Working memory	Psychopathy
Community affairs, home and hobbies, and personal care	Orientation	Memory	Executive function	

Of these endpoints: CDR-SOB, MMSE and RAVLT results are expected to be most valued by potential strategic partners

1. CDR-SOB, while also considered a "gold standard" endpoint in Alzheimer's disease research, was not selected as a primary endpoint to avoid duplication, as it constitutes about half the ADCOMS score weighting

Validity of XanADu's endpoints

XanADu endpoints are validated cognitive outcome measures and results will be highly valued by clinicians and potential strategic partners alike

Endpoints are validated and accepted by global regulatory bodies, academics and potential strategic partners

- ✓ **FDA recognises and accepts all the XanADu endpoints**, and does not require an endpoint biomarker
- ✓ ADAS-COG14 and CDR-SOB are considered the **"gold standard" endpoints**
- ✓ Potential strategic partners will find **ADCOMS result interesting** as it is derived from well-established endpoints
- ✓ Potential **strategic partners have expressed strong interest** to learn more about XanADu and Xanamem

Multiple strategic partners are currently interested to review and consider the XanADu results and data. Actinogen is well positioned to commence strategic discussions for further clinical development

Interim analysis

Positive recommendations from the DSMB[1] reflect confidence in the safety of the drug and the design of the XanADu study. Supports the broader development of Xanamem

First DSMB review (23 May 2018)

- Evaluation of 50 patients' safety and efficacy data reviewed by an independent DSMB[2]
- **Recommendation by DSMB to continue XanADu without modification**

Second DSMB review (22 August 2018)

- Evaluation of 125 patients' safety data
- **Reaffirmed continuation of XanADu without modification**

Third DSMB review

- Expected to be completed in early CY2019

Positive DSMB recommendations underpin the XanADu study and further development of Xanamem in other indications

1. DSMB: Data Safety Monitoring Board
2. Evaluable patients to have completed the study – note: an additional 37 patients' safety data was also included in the analysis (data was from patients still ongoing in the study)

Market dynamics of Alzheimer's disease

Presents a compelling commercial opportunity for Actinogen to target initially

Substantial target market with significant upside[1]

Cortisol-high, cognition normal	Subjective memory decline	Cognitive and functional decline fulfilling dementia		
At-risk	Prodromal	Mild	Moderate	Severe
~25.0m (50% over 65 yrs)	**~4.0m**	**~1.5m**	~1.7m	~2.5m

Upside potential for earlier use *Key focus*

>US$7.5bn

Target annual peak sales (mild AD)[2]

Underpinned by favourable market dynamics

- ✓ Targeting **large addressable** markets (US, EU5, JP)
- ✓ All **currently approved drugs are symptomatic treatments** (that do not affect disease progression) **providing limited benefit**
- ✓ Treatment **prices are robust** (despite generic competition) – with users paying for modest clinical efficacy

US branded products (gross price)

US$10/day

US$8/day

US$18/day

Source: Drugs.com, Biogen, Roche, Datamonitor, Alzheimer's Association

1. Target market statistics based on the current US treatment landscape
2. Base case annual peak sales assumes: (1) Launch: US 2024, EU5, JP and ROW 2025; (2) Penetration: 30% of mild AD market in 5 years (i.e. ~470,000 in the US); (3) Pricing: US – US$19/day gross (US$12/day net), ROW: 50% of US price

Development pipeline of other cognitive enhancers

Xanamem is one of the most advanced cognitive enhancers currently in development[1]

Company	Drug candidate	Mechanism	Phase (status)	Primary endpoint(s)	Upcoming milestones[2]
Actinogen Medical	**Xanamem**	**11βHSD1 inhibitor**	**II (ongoing)**	**ADAS-Cog14, ADCOMS**	**April 2019** — **Results available by mid CY2019**; Estimated primary completion April 2019
SUVEN Life Sciences	SUVN-502	5HT6 antagonist	II (ongoing*)	ADAS-Cog11	**April 2019** — Estimated primary completion; *Target to complete patient recruitment by end CY2018
EIP Pharma	Neflamapimod	p38 MAPK inhibitor	II (ongoing)	HVLT-R[4]	**June 2019** — Estimated primary completion
Neurotrope Bioscience	Bryostatin 1	Protein Kinase C Epsilon activator	II[3] (ongoing)	SIB[4]	**July 2019** — Estimated primary completion[3]
biohaven pharmaceuticals	BHV4157	Na+ channel blocker	II / III (ongoing)	ADAS-Cog11	**January 2020** — Estimated primary completion
Boehringer Ingelheim	BI425809	Glycine transport inhibitor	II (ongoing)	ADAS-Cog11	**February 2020** — Estimated primary completion
AGENEBIO	AGB101	SV2A	III (ongoing)	CDR-SOB	**November 2021** — Estimated primary completion
Green Valley	GV-971	Unknown	III**	ADAS-Cog12	**Phase III trial conducted in China successfully completed September 2018 /international trial planned
anavex Life Sciences	Anavex 2-73	SIGMAR1 agonist	IIa	MTD[4]	Initiation of Phase IIb / III announced in August 2018 – no evidence in clinical trial registries
Allergan / HEPTARES Therapeutics	HTL0018318	M1 agonist	II***	N/A***	***Phase II trial put on hold in September 2018 prior to initiation due to unexpected primate toxicology

1. Some programs that may be relevant are not included due to lack of development (e.g. Sinphar Pharmaceuticals: STA-1; Allergan: CPC-201) or because they are more commonly referred to as disease modifying therapies (e.g. Cognition Therapeutics: CT1812; Daehwa Pharma: DHP1401; Agene Bio: AGB101)
2. Estimated primary completion based on clinicaltrials.gov information – unless additional information is available
3. Completed Phase II in May 2017 with equivocal results. New Phase II initiated in June 2018 with primary completion expected in July 2019
4. HVLT-R: Hopkins Verbal Learning Test – Revised; SIB: Severe Impairment Battery; MTD: Maximum Tolerated Dose

Comparison of Alzheimer's disease treatments

Actinogen's novel treatment for Alzheimer's disease is clearly differentiated and may be used in combination with existing cognitive enhancers and potential anti-amyloid drugs (currently in development)

Overview

	Xanamem	Cognitive enhancers	Anti-amyloid drugs
Status	**In development**	In market[1]	In development
Mechanism of action	**Targets cortisol**	AChE[2] inhibitors, NMDA[2] receptor antagonist	Anti-amyloid
Administration	**Oral (small molecule)**	Oral (small molecule)	Injectable IV / SC[3] (biologics)
Evidence of disease modification	✓[4]	✗	✓
Duration of effect (>8 months)	✓[4]	?	✓
Potential to treat 'at risk' patients	✓	✗	✓
Applicable to other cognitive disorders	✓	✗	✗
No SAEs identified	✓	✗	✗
No biomarker required	✓	✓	✗
Low cost of goods	✓	✓	✗

1. Analysis excludes other cognitive enhancers currently in development
2. AChE: acetylcholinesterase; NMDA: N-methyl-D-aspartate
3. IV: intravenous; SC: subcutaneous
4. Evidence of disease modification and duration based on animal model studies

Xanamem may support potential combination therapy, with existing treatments and other drugs currently in development, to improve patient outcomes

- Approved cognitive enhancers have different mechanism of action and varying degrees of benefit and duration
- Despite promising data, anti-amyloid therapy has high costs, compliance challenges and requires IV / SC administration

Significant headwinds for BACE inhibitor development

Significant opportunity for Xanamem development, with recent study data indicating that anti-amyloid may not be efficacious as initially expected

Overview[1]

- Results indicate **potent anti-amyloid activity has not translated to substantial cognitive benefit**
- **Trending / actual cognitive worsening was observed** across multiple compounds

Company	Compound (Phase) *Status*	Population	CSF Aβ lowering range	Cognition comments
MERCK	Verubecestat (III) *Stopped for futility*	Mild moderate	60% - 80%	**Early:** Trend for cognitive worsening **Overall:** No difference
		Prodromal	60% - 80%	**Early:** Cognitive worsening **Overall:** Cognitive worsening
Lilly AstraZeneca	Lanabecestat (III) *Stopped for futility*	Prodromal – mild	55% - 75%	**Early:** Trend for cognitive worsening **Overall:** Data not locked
		Mild	55% - 75%	
Johnson & Johnson	Atabecestat (III) *Stopped for hepatic safety*	Cognitively unimpaired	50% - 82%	**Early:** Trend for cognitive worsening - Cognitive worsening **Overall:** Dosing discontinued
Lilly	LY3202626 (II) *Stopped for futility*	Mild dementia	70% - 90%	**Early:** Trend for cognitive worsening - Equivocal **Overall:** Dosing discontinued
Eisai Biogen	Elenbecestat (III) *Ongoing*	Mild moderate	~60%	**Early:** Trends for improvement **Overall:** General trends for improvement
AMGEN NOVARTIS	CNP520 (II/III) *Ongoing*	Cognitively unimpaired	20% - 90%	**Early:** Not applicable **Overall:** No difference

1. Information presented at CTAD (Clinical Trials on Alzheimer's Disease) Conference held in Barcelona in October 2018

Big Pharma interest

Global Big Pharma demonstrating strong M&A interest in acquiring or partnering with companies and licensing novel mechanism of action assets with Alzheimer's disease as the lead/key indication



Deal value (US$bn)	0.2	0.5	0.5	0.5	0.7	0.7	0.8	1.0	1.1	1.2	1.9	3.3	3.5
Bidder / Licensee	abbvie	Lilly	janssen	MERCK	Biogen	PIERIAN	Otsuka	Allergan	abbvie	Takeda	Lilly	Allergan	Otsuka
Target / Licensor	ALECTOR	AstraZeneca	AC Immune	Bionomics	Bristol-Myers Squibb	Bristol-Myers Squibb	Lundbeck	CHASE Pharmaceuticals Corporation	Voyager THERAPEUTICS	DENALI	AC Immune	HEPTARES therapeutics	AVANIR
Year	2017	2014	2015	2014	2017	2014	2013	2016	2018	2018	2018	2016	2014
Deal type	Partnership	Partnership	Partnership	Partnership	Licence	Asset	Partnership	Acquisition	Partnership	Partnership	License	License	Acquisition
Candidate	Immuno-neurology platform	AZD3293	ACI-35	BNC-375	BMS-986168	IPN007	LU AE58054	CPC-201	Gene Therapy platform	Brain-penetrant ATV	ACI-3024	Three M1/M4 agonists	AVP-786
Phase	Pre-clinical	I	I	Pre-clinical	I	Pre-clinical	II	II	Pre-clinical	Pre-clinical	Pre-clinical	I	III
Novel MoA (not anti-amyloid)	✓	✗	✗	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

Development pipeline

Additional Xanamem studies

Other potential indications

Additional value-adding Xanamem studies

Actinogen is focused on completing nine key additional studies to enhance the Xanamem data set, which can also be potentially leveraged into other indications

Target occupancy studies

Aims to accurately demonstrate the effect different doses of Xanamem has on inhibiting the 11β-HSD1 enzyme In the human brain and to optimise Xanamem dosing

Currently underway with **results expected in 2Q CY2019**

XanaHES

Higher dose safety study

To expand the safety data-set for Xanamem and explore potential for higher doses of the drug to be used in Alzheimer's and other indications

XanaHES study initiated with **initial results expected in 2Q CY2019**

Further safety / toxicology studies

To allow for longer treatment periods, as routinely required by global regulatory authorities in the development of any drug

Additional studies initiated with **results expected in 6-12 months**

Actinogen is fully funded to complete these additional Xanamem studies

Other potential indications

Actinogen is also focused on developing Xanamem in other indications to optimise shareholder value

Overview

- Multiple potential target indications beyond Alzheimer's represent significant market expansion opportunities
- Growing literature on cortisol-induced cognitive impairment associated with many conditions
- Actinogen undertaking a detailed review to identify best additional target indications
- Development program leverages existing data from earlier clinical programs

Possible target indications

Depression	Diabetes
Schizophrenia	Parkinson's disease
POCD & TBI [1]	Post-MI, PVD Stroke & HT [2]
Down syndrome	And more..

Preliminary assessment currently underway to identify high priority indications for development

1. Post-operative cognitive decline & Traumatic brain injury
2. Post-myocardial infarction, Peripheral vascular disease & Hypertension (peripheral & intra-cranial)

Development pipeline

Multiple studies are currently underway to enhance the Xanamem data set, with results expected in 2Q CY2019, and preliminary decision on assessment of other indications planned for 1Q CY2019



Outlook

Upcoming catalysts

Key investment highlights

Development and commercialisation strategy

Actinogen is focused on progressing Xanamem clinical development, while continually assessing potential value accretive opportunities to optimise shareholder value

Xanamem clinical development

Progress Xanamem development in Alzheimer's disease and potential studies into other target indications[1]

Fully funded to complete XanADu and all new studies underway, including target occupancy and XanaHES, that will inform the next stage of development

License / partnering

Proactive and strategic engagement with prospective development and commercialisation partners to advance Xanamem development

Discussions currently underway with many major companies and leading developers of drugs for Alzheimer's disease

Actinogen is well positioned to deliver significant potential value uplift to shareholders

1. Subject to data / results

Upcoming catalysts

Significant upcoming milestones across first half 2019



Actinogen is fully funded to complete XanADu and other key studies

Key investment highlights

Actinogen is developing innovative treatments for cognitive impairment associated with neurodegenerative and metabolic diseases with an initial focus on Alzheimer‘s disease

Xanamem - lead compound

Differentiated with a novel mechanism of action
First-in-class, brain penetrant, orally active, small molecule, inhibitor of 11βHSD1 enzyme
Xanamem mechanism of action validated by independent research on the cortisol hypothesis

Targeted strategic market focus

Initially focused on developing a treatment for Alzheimer's disease
Addressable market worth >US$7.5bn with unmet needs and potential upside
Target indication underpinned by efficacy results from animal model studies

Clinical stage asset

Advanced clinical stage program assessing Xanamem in Alzheimer’s disease
XanADu clinical trial fully enrolled, with results expected Q2 CY2019
Positive safety interim analysis reported in XanADu

Potential value upside

Well positioned to unlock further value
Multiple potential indications
Significant Big Pharma interest

De-risked opportunity

Fully funded programs
Additional Xanamem-related studies initiated
Additional pipeline opportunities under evaluation

Experienced leadership

Board and Management with significant drug development and corporate experience, supported by key opinion leaders and Xanamem discovery team

Appendix

Corporate overview

Senior leadership

Advisory boards

IP protection



Corporate overview

Actinogen is an ASX-listed biotech company focused on innovative approaches to treating cognitive impairment associated with chronic neurodegenerative and metabolic diseases

Overview

- Actinogen is developing Xanamem, a novel therapy for Alzheimer's disease with significant market potential
- Actinogen is completing a Phase II double-blind, 12 week, randomised, placebo-controlled study (XanADu) in Alzheimer's disease
- XanADu is designed to assess the safety, tolerability and efficacy of Xanamem in subjects with mild Alzheimer's disease

Key shareholding metrics



BVF Partners

Top 20 (excl. BVF Partners)

australianethical FIL[1] Platinum Asset Management

Remaining shareholders

LTM share price performance and trading metrics



Share price (13 March 2019)	A$0.054
No. of shares	1,117.9m
Market cap.	A$60.4m
Net debt / (net cash)[2]	(A$15.5m)
Enterprise Value	A$44.8m

1. FIL Investment Management (Hong Kong) Limited and FIL Pensions Management
2. Net cash as at 31 Dec 2018

Substantial Institutional investment in Actinogen*

Recognises potential and endorses strategy

Positive interim analysis catalyses significant $15M investment through Placement

Leading investors enter register:

- USA specialist biotech investor **Biotechnology Value Fund L.P.**
- Australian institutions **Platinum Investments Management** and **Australian Ethical Investment**

Strong endorsement - Placement price represents a **13.4% premium** to the 5-day VWAP

BVF cornerstones Placement - largest shareholder with a **19.97% holding**

Funding to advance the development plan through additional Xanamem studies.

* Announced 23 May 2018

Board of Directors

Commercially experienced and globally recognised leadership team with decades of experience in drug development and biotech investment

Dr. Geoff Brooke

Chairman

- **30+ years experience** in the healthcare investment industry
- Founder and MD of Medvest Inc and GBS Venture Partners
- Significant expertise in biotech: development strategy, capital raising and investments
- MBBS (University of Melbourne); MBA (IMEDE, Switzerland)

Dr. Bill Ketelbey

CEO & MD

- **30+ years experience** in healthcare, biotech and pharmaceutical industries
- Formerly senior international roles at Pfizer; Director at the Westmead Institute of Medical Research
- Involved in clinical development and commercialisation of Aricept™
- MBBCh (University of Witwatersrand); FFPM; MBA (Macquarie); GAICD

Dr. George Morstyn

Non-executive director

- **25+ years experience** in biotechnology investment and drug development
- Board member of Cancer Therapeutics, Symbio and Biomedvic; Former Senior VP and SMO at Amgen
- Global responsibility for Amgen's drug development in all therapeutic areas
- MBBS (Monash University); PhD (Walter and Eliza Hall Institute); FRACP; MAICD

Advisory Boards

World's premier academics involved in the development of Xanamem and as a novel treatment for Alzheimer's disease

Xanamem™ Clinical Advisory Board

Positions Xanamem at the forefront of Alzheimer's drug development

Prof. Craig Ritchie *Chair*

THE UNIVERSITY of EDINBURGH

Prof. Colin Masters *AO*

THE UNIVERSITY OF MELBOURNE

The Royal Melbourne Hospital

THE FLOREY INSTITUTE OF NEUROSCIENCE & MENTAL HEALTH

Prof. Jeffrey Cummings

Cleveland Clinic

Scientific Advisory Board

Combining deep understanding of cortisol, 11β-HSD1 and drug discovery

Prof. Jonathan Seckl

THE UNIVERSITY of EDINBURGH

Prof. Brian Walker

Newcastle University

Prof. Scott Webster

THE UNIVERSITY of EDINBURGH

Proactive strategic business development

Actinogen Medical

Continued strategic engagement with prospective development and commercial partners in the lead up to XanADu results

Progressing collaboration and commercial discussions with prospective big pharma partners, and presenting to, and educating the scientific community

Planned H1 CY2019
Partnering and Investment Conference Attendance

JP Morgan Healthcare Conference | January, San Francisco

SACHS Neuroscience | January, San Francisco | Oral Presentation

BIO-Europe Spring 2019 | March, Vienna

BIO 2019 | June, Philadelphia

13TH ANNUAL INTERNATIONAL PARTNERING CONFERENCE
BIO-EUROPE SPRING®

SACHS ASSOCIATES 2 NEUROSCIENCE INNOVATION FORUM
For BD&L and Investment in Therapeutics and Technology
6th Jan 2019 | Marines' Memorial Club, SF | USA

Planned CY2019
Scientific Conference Attendance

AD/PD 2019 | March, Lisbon

AAIC 2019 | July, Los Angeles

CTAD 2019 | December, San Diego

IP protection

Actinogen maintains a broad granted composition of matter patent estate, extending to at least 2031, with key patents granted in all major target markets

Geographic patent overview



- Actinogen's patent portfolio **covers a broad range of neurological and metabolic diseases** including Alzheimer's disease
- Xanamem **patents granted in key markets** that account for over 90% of the global Alzheimer's market
- **Actinogen's patent portfolio extends to at least 2031**

>90% of the global Alzheimer's disease market

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Actinogen and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).